Application of Memory Natural Killer Cells in HIV Vaccine
DOI:
https://doi.org/10.54097/pvyfyq59Keywords:
HIV; vaccine; NK cells; NK memory cells.Abstract
Human immunodeficiency virus (HIV) is a formidable infection targeting the intricate defense mechanisms of the human body, primarily focusing its assault on the vital white blood cells known as CD4 cells. HIV impairs these CD4 cells, reducing resistance to opportunistic infections. In 2022, 630,000 people died from HIV-related causes globally due to the lack of preventative vaccines and effective treatment. The pursuit of an effective HIV vaccine remains a critical endeavor in global health, necessitating innovative strategies that can elicit robust and durable immune responses. Natural killer (NK) cells, renowned for their swift and inherent cytotoxic prowess, constitute a critical element of innate immunity, typically thought to be deficient in memory abilities. Fascinatingly, NK cells have now become the focal point of scientific research due to emerging evidence suggesting the presence of memory-like characteristics within their functional repertoire. Through a comprehensive exploration of NK cell subpopulations and the strategic application of cytokines or other stimuli to induce the development of memory-generating NK cell subpopulations, the potential for enhancing the efficacy of HIV vaccines emerges. This approach holds promise in bolstering the creation of adaptive immunity and advancing the quest for effective HIV immunization strategies. The study offers valuable insights into the potential of NK memory cells as a viable component of future HIV vaccine regimens, suggesting avenues for further research and development in the quest to mitigate the global burden of HIV.
Downloads
References
Rr, A. et al. Mapping the Interplay between NK Cells and HIV: Therapeutic Implications. J. Leukoc. Biol. 2023, 113 (2).
Cooper, M. A. et al. Cytokine-Induced Memory-like Natural Killer Cells. Proc. Natl. Acad. Sci. U. S. A. 2009, 106 (6), 1915–1919.
Ni, J. et al. Adoptively Transferred Natural Killer Cells Maintain Long-Term Antitumor Activity by Epigenetic Imprinting and CD4+ T cell Help. Oncoimmunology 2016, 5 (9), e1219009.
Uppendahl, L. D. et al. Cytokine-Induced Memory-like Natural Killer Cells Have Enhanced Function, Proliferation, and in Vivo Expansion against Ovarian Cancer Cells. Gynecol. Oncol. 2019, 153 (1), 149–157.
Ewen, E.-M. et al. KIR Downregulation by IL-12/15/18 Unleashes Human NK Cells from KIR/HLA-I Inhibition and Enhances Killing of Tumor Cells. Eur. J. Immunol. 2018, 48 (2), 355–365.
Kakuda, T. et al. Senescent CD8+ T Cells Acquire NK Cell-like Innate Functions to Promote Antitumor Immunity. Cancer Sci. 2023, 114 (7), 2810–2820.
Millan, A. J. et al. Evidence for Prescribed NK Cell Ly-49 Developmental Pathways in Mice. J. Immunol. Baltim. Md 1950 2021, 206 (6), 1215–1227.
Reeves, R. K. et al. Antigen-Specific NK Cell Memory in Rhesus Macaques. Nat. Immunol. 2015, 16 (9), 927–932.
Agosto, L. M. et al. CD4+ T cell Subsets and Pathways to HIV Latency. AIDS Res. Hum. Retroviruses 2018, 34 (9), 780–789.
Lee, J. et al. Epigenetic Modification and Antibody-Dependent Expansion of Memory-like NK Cells in Human Cytomegalovirus-Infected Individuals. Immunity 2015, 42 (3), 431–442.
Harrison, G. F. et al. Allele Imputation for the Killer Cell Immunoglobulin-like Receptor KIR3DL1/S1. PLoS Comput. Biol. 2022, 18 (2), e1009059.
Hagemann, K. et al. Natural Killer Cell-Mediated ADCC in SARS-CoV-2-Infected Individuals and Vaccine Recipients. Eur. J. Immunol. 2022, 52 (8), 1297–1307.
Zf, C. et al. A Novel Endogenous CD16-Expressing Natural Killer Cell for Cancer Immunotherapy. Biochem. Biophys. Rep. 2021, 26.
Lisovsky, I. et al. Differential Contribution of Education through KIR2DL1, KIR2DL3, and KIR3DL1 to Antibody-Dependent (AD) NK Cell Activation and ADCC. J. Leukoc. Biol. 2019, 105 (3), 551–563.
Haroun-Izquierdo, A. et al. Adaptive Single-KIR+NKG2C+ NK Cells Expanded from Select Superdonors Show Potent Missing-Self Reactivity and Efficiently Control HLA-Mismatched Acute Myeloid Leukemia. J. Immunother. Cancer 2022, 10 (11), e005577.
Zhen, A. et al. HIV-Specific Immunity Derived From Chimeric Antigen Receptor-Engineered Stem Cells. Mol. Ther. J. Am. Soc. Gene Ther. 2015, 23 (8), 1358–1367.
Downloads
Published
Issue
Section
License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.







